"Advocate Secures $100M for Medical Ecstasy Research"
TL;DR
The Multidisciplinary Association for Psychedelic Studies (MAPS) has successfully raised over $100 million through a Series A private stock sale to fund the final phase of regulatory approval for MDMA (Ecstasy) as a treatment for post-traumatic stress disorder (PTSD). This significant financial milestone underscores the growing interest and investment in the therapeutic potential of psychedelics.
Topics:businesshealth-and-medicine##fundraising#health-and-medicine#maps#mdma#psychedelicstudies#ptsdtreatment
Ecstasy-for-Medicine Advocate Raises $100 Million - WSJ The Wall Street JournalView Full Coverage on Google News
Want the full story? Read the original reporting
Read on The Wall Street Journal